Literature DB >> 26296596

Osteonecrosis of the Jaw in Association With Chemotherapy in the Setting of Cutaneous T-Cell Lymphoma.

Christopher R DeSesa1, Suganya Appugounder2, Christel Haberland3, Michael P Johnson4.   

Abstract

T-cell lymphomas (TCLs) account for approximately 15 to 20% of all non-Hodgkin lymphomas in the United States. The most common form of TCL is cutaneous TCL (CTCL), with Sézary syndrome and mycosis fungoides being the most prevalent subtypes. Sézary syndrome is the more aggressive form and often is referred to as a late-stage variant of mycosis fungoides. Clinically, it is characterized by diffuse erythroderma, cutaneous edema, pruritus, nonhealing cutaneous ulcers, and lymphadenopathy. Patients also can present with changes to their nails, hyperpigmentation, alopecia, palmoplantar keratoderma, ectropion, and hepatosplenomegaly. The overall prognosis for patients with Sézary syndrome is poor. The literature regarding oral manifestations of CTCL mostly report those of mycosis fungoides because it is the most common subtype of CTCL. Currently, there are only 2 reports in the scientific literature of intraoral manifestations of Sézary syndrome. This case report describes a patient with Sézary syndrome who presented with rapidly progressing erythematous lesions of the gingiva and multifocal osteonecrosis of the maxilla and mandible. This is the third reported case of an intraoral manifestation of Sézary syndrome and the first reported case of osteonecrosis in the setting of CTCL.
Copyright © 2016 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26296596     DOI: 10.1016/j.joms.2015.07.019

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  5 in total

Review 1.  Non-antiresorptive drugs associated with the development of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis.

Authors:  Isti Rahayu Suryani; Iraj Ahmadzai; Sohaib Shujaat; Hongyang Ma; Reinhilde Jacobs
Journal:  Clin Oral Investig       Date:  2022-01-11       Impact factor: 3.573

2.  Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.

Authors:  Ourania Nicolatou-Galitis; Maria Kouri; Erofili Papadopoulou; Emmanouil Vardas; Dimitra Galiti; Joel B Epstein; Sharon Elad; Giuseppina Campisi; Nikolaos Tsoukalas; Kivanc Bektas-Kayhan; Winston Tan; Jean-Jacques Body; Cesar Migliorati; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2018-10-23       Impact factor: 3.603

3.  Medication-related osteonecrosis of the jaw (MRONJ) and eNOS Polymorphisms in multiple myeloma patients: a single center experience.

Authors:  Betul Taş Ozyurtseven; Istemi Serin; Ayse Feyda Nursal; Sacide Pehlivan; Mustafa Pehlivan
Journal:  BMC Oral Health       Date:  2021-05-18       Impact factor: 2.757

4.  Risk factors for multi-joint disease in patients with glucocorticoid-induced osteonecrosis.

Authors:  A Krez; J Lane; A Heilbronner; K-H Park-Min; K Kaneko; T Pannellini; D Mintz; D Hansen; D J McMahon; K A Kirou; G Roboz; P Desai; R S Bockman; E M Stein
Journal:  Osteoporos Int       Date:  2021-04-20       Impact factor: 4.507

5.  Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and/or Targeted Drugs Increases the Risk for Stage 3 Medication-Related Osteonecrosis of the Jaw: A 4-Year Retrospective Study.

Authors:  Yuqiong Zhou; Yejia Yu; Yueqi Shi; Mengyu Li; Chi Yang; Shaoyi Wang
Journal:  Biomed Res Int       Date:  2020-10-15       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.